BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO - US0905722072 - Common Stock
292.84 USD
-3.76 (-1.27%)
292.84 USD
0 (0%)
Overall BIO gets a fundamental rating of 4 out of 10. We evaluated BIO against 54 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
In the past year BIO had a positive cash flow from operations.
In multiple years BIO reported negative net income over the last 5 years.
BIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIO has a better Return On Assets (3.12%) than 68.52% of its industry peers.
The Return On Equity of BIO (4.47%) is better than 68.52% of its industry peers.
BIO has a better Return On Invested Capital (2.36%) than 61.11% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 16.00%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROIC | 2.36% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
Looking at the Profit Margin, with a value of 12.49%, BIO is in the better half of the industry, outperforming 79.63% of the companies in the same industry.
With a decent Operating Margin value of 11.30%, BIO is doing good in the industry, outperforming 68.52% of the companies in the same industry.
BIO's Operating Margin has been stable in the last couple of years.
BIO has a better Gross Margin (53.00%) than 61.11% of its industry peers.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
Compared to 5 years ago, BIO has less shares outstanding
Compared to 1 year ago, BIO has a worse debt to assets ratio.
2.2 Solvency
BIO has an Altman-Z score of 3.24. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.24, BIO is doing good in the industry, outperforming 68.52% of the companies in the same industry.
The Debt to FCF ratio of BIO is 3.46, which is a good value as it means it would take BIO, 3.46 years of fcf income to pay off all of its debts.
BIO has a better Debt to FCF ratio (3.46) than 74.07% of its industry peers.
BIO has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
BIO has a Debt to Equity ratio of 0.17. This is comparable to the rest of the industry: BIO outperforms 59.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 3.24 |
ROIC/WACC0.23
WACC10.22%
2.3 Liquidity
BIO has a Current Ratio of 5.12. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO has a better Current ratio (5.12) than 70.37% of its industry peers.
BIO has a Quick Ratio of 3.67. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO's Quick ratio of 3.67 is fine compared to the rest of the industry. BIO outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.11%.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
Looking at the last year, BIO shows a decrease in Revenue. The Revenue has decreased by -0.33% in the last year.
BIO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
3.2 Future
The Earnings Per Share is expected to decrease by -2.55% on average over the next years.
The Revenue is expected to grow by 1.48% on average over the next years.
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.32%
EPS Next 5Y-2.55%
Revenue Next Year0.65%
Revenue Next 2Y1.77%
Revenue Next 3Y2.22%
Revenue Next 5Y1.48%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 29.11, the valuation of BIO can be described as expensive.
BIO's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 66.67% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.14, BIO is valued at the same level.
The Price/Forward Earnings ratio is 28.19, which means the current valuation is very expensive for BIO.
BIO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 64.81% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.80, BIO is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.11 | ||
| Fwd PE | 28.19 |
4.2 Price Multiples
BIO's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BIO is cheaper than 79.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.8 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.71
EPS Next 2Y0.38%
EPS Next 3Y3.32%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
292.84
-3.76 (-1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change-2.61%
Ins Owners3.77%
Ins Owner Change0%
Market Cap7.92B
Analysts76.36
Price Target332.18 (13.43%)
Short Float %4.94%
Short Ratio2.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.02%
Min EPS beat(2)38.97%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)40.05%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)26.32%
EPS beat(12)8
Avg EPS beat(12)16.87%
EPS beat(16)12
Avg EPS beat(16)20.5%
Revenue beat(2)2
Avg Revenue beat(2)2.99%
Min Revenue beat(2)1.11%
Max Revenue beat(2)4.87%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-1.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.6%
Revenue beat(16)6
Avg Revenue beat(16)-0.34%
PT rev (1m)3.55%
PT rev (3m)-0.41%
EPS NQ rev (1m)13.02%
EPS NQ rev (3m)-25.11%
EPS NY rev (1m)14.35%
EPS NY rev (3m)11.99%
Revenue NQ rev (1m)3.05%
Revenue NQ rev (3m)-1.08%
Revenue NY rev (1m)3.03%
Revenue NY rev (3m)2.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.11 | ||
| Fwd PE | 28.19 | ||
| P/S | 3.1 | ||
| P/FCF | 22.8 | ||
| P/OCF | 14.82 | ||
| P/B | 1.11 | ||
| P/tB | 1.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.06
EY3.44%
EPS(NY)10.39
Fwd EY3.55%
FCF(TTM)12.84
FCFY4.39%
OCF(TTM)19.76
OCFY6.75%
SpS94.39
BVpS263.44
TBVpS227.28
PEG (NY)N/A
PEG (5Y)3.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROCE | 2.99% | ||
| ROIC | 2.36% | ||
| ROICexc | 2.75% | ||
| ROICexgc | 3.12% | ||
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% | ||
| FCFM | 13.61% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | -6.2 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 108.94% | ||
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 3.24 |
F-Score6
WACC10.22%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.32%
EPS Next 5Y-2.55%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
Revenue Next Year0.65%
Revenue Next 2Y1.77%
Revenue Next 3Y2.22%
Revenue Next 5Y1.48%
EBIT growth 1Y-15.48%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year31.72%
EBIT Next 3Y14.89%
EBIT Next 5Y7.18%
FCF growth 1Y125.65%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y86.4%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%